Chicago will enact a new
requirement that all pharmaceutical sales reps maintain a license based on
their training for ethics, marketing regulations and industry laws; at a cost
of $750, the reps will be responsible for applicable fees and annual renewals.
The new ordinance also requires paperwork to be filed with the city regarding
the reps’ activities and physician contact. The new regulations come after
Chicago filed lawsuits against multiple drug manufacturers and their role in
the current opioid epidemic. The fees are expected to exceed $1 million for the
city, which will then be used to support ongoing education efforts, regulatory
costs and expanding treatment availability for addicts. The pharmaceutical
industry argues that the new requirements do nothing to curb opioid abuse.
Read a Stat News article on it here.
No comments:
Post a Comment